Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer Competes With Canadian Imports On Price With “Pfriends” Program

Executive Summary

Pfizer is offering discounts on medicines to low-income uninsured patients that are competitive with widely available prices of Canadian imports

You may also be interested in...

FDA Will Create “Limited” Rx Import System, Ex-CMS Head Predicts

The Bush Administration will initiate a "limited" pharmaceutical importation program during 2004, former Centers for Medicare & Medicaid Services Administrator Tom Scully predicted during the Medco drug trend symposium May 18 in Lake Buena Vista, Fla

U Share Card Has Best Prices On Pfizer, Lilly Brands In Latest Medicare Data

The "U Share" Medicare-endorsed discount card is offering the lowest prices on most Pfizer and Lilly prescription drug brands, according to updated pricing data posted on the Centers for Medicare & Medicaid Services website May 17

Import Portents Aligning: HHS Secretary Says Law May Be Unstoppable

HHS Secretary Thompson is predicting that Congress will enact a pharmaceutical import law in 2004, despite his concerns with the idea





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts